Molecular subtyping of Alzheimer’s disease using RNA sequencing data reveals novel mechanisms and targets

Author(s): Neff, RA; Wang, M; Vatansever, S; Guo, L; Ming, C; Wang, Q; Wang, E; Horgusluoglu-Moloch, E; Song, W; Li, A; Castranio, EL; Tcw, J; Ho, L; Goate, A; Fossati, V; Noggle, S; Gandy, S; Ehrlich, ME; Katsel, P; Schadt, E; Cai, D; Brennand, KJ; Haroutunian, V; Zhang, B;
Year: 2021;  
Journal: Science Advances;  
Volume: 7;  
Issue: 2;  

Alzheimer’s disease (AD), the most common form of dementia, is recognized as a heterogeneous disease with diverse pathophysiologic mechanisms. In this study, we interrogate the molecular heterogeneity of AD by analyzing 1543 transcriptomes across five brain regions in two AD cohorts using an integrative network approach. We identify three major molecular subtypes of AD corresponding to different combinations of multiple dysregulated pathways, such as susceptibility to tau-mediated neurodegeneration, amyloid-β neuroinflammation, synaptic signaling, immune activity, mitochondria organization, and myelination. Multiscale network analysis reveals subtype-specific drivers such as GABRB2, LRP10, MSN, PLP1, and ATP6V1A We further demonstrate that variations between existing AD mouse models recapitulate a certain degree of subtype heterogeneity, which may partially explain why a vast majority of drugs that succeeded in specific mouse models do not align with generalized human trials across all AD subtypes. Therefore, subtyping patients with AD is a critical step toward precision medicine for this devastating disease.